Tag: rare diseases
-

Sanofi’s Infilbray Wins FDA Approval for Neurological Symptoms of Type 3 Gaucher Disease
Sanofi’s Infilbray becomes the first FDA-approved treatment for neurological manifestations of Type 3 Gaucher disease. Explore its mechanism, Phase 3 findings and significance for patients.
-

AstraZeneca Keeps Its $80 Billion Goal Despite a Major Trial Setback
AstraZeneca reaffirmed its $80 billion revenue ambition after reporting solid second-quarter results. Strong oncology and rare disease sales helped restore confidence following the failure of a major Wainua trial.
-

Eli Lilly Strikes $475 M Gene Therapy Deal with MeiraGTx for Rare Retinal Disease
Eli Lilly’s $475 million acquisition of MeiraGTx marks a bold step into next-generation gene therapies targeting rare retinal diseases. Despite challenges in the gene therapy market, the move reflects growing optimism about using advanced genetic tools to improve the lives of patients with rare inherited disorders.